Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367965 · ClinicalTrials.gov registry record · Phase 3
Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
NCT00367965 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 153 participants.
The verdict
NCT00367965, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
Study Summary
To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).
Interventions
- DRUG placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2004-02 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367965
The ClinicalTrials.gov registry entry for NCT00367965 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00367965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00367965 about?
NCT00367965 is a clinical study titled "Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis". To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).
What is the current status of trial NCT00367965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2004-02. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00367965?
The interventions under investigation include: placebo (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00367965?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.